-+ 0.00%
-+ 0.00%
-+ 0.00%

Artelo Biosciences Issued Notification Of Allowance From Japanese Patent Office With Decision To Grant Patent Application For Commercial Formulation Of ART27.13

Benzinga·08/20/2026 12:53:28
Listen to the news

Artelo Biosciences, Inc. (Nasdaq: ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that the Japanese Patent Office has issued a notification of allowance with a Decision to Grant for the Company’s patent application covering the intended Commercial Formulation Of ART27.13, Artelo’s peripherally selective dual cannabinoid agonist currently being evaluated in two Phase 2 clinical trials.